High-risk fund adjusts organization to stay on top of its game

Fresh off of promoting several team members to partners, life science venture capital fund HealthCap's founder Björn Odlander talks to AMWatch about new strategy developments and why pension funds and endowments keep returning to the firm's high-risk family of VC funds. He is, however, tight-lipped about past performance.
Dr. Björn Odlander, founder and partner of Healthcap | Photo: PR / Healthcap/Dan Coleman AB
Dr. Björn Odlander, founder and partner of Healthcap | Photo: PR / Healthcap/Dan Coleman AB

Swedish venture capital firm HealthCap specializes in investing in companies that try to find and develop medical solutions to serious diseases such as cancer and genetic diseases.

It's a strategy the firm has had for a long time, and the decision was recently made to expand the team and promote several new partners to advance the efforts.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Further reading